# Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

> **NCT04185883** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Amgen** · enrollment: 610 (actual)

## Conditions studied

- Advanced Solid Tumors
- Kirsten Rat Sarcoma (KRAS) pG12C Mutation

## Interventions

- **DRUG:** Sotorasib
- **DRUG:** Trametinib
- **DRUG:** RMC-4630
- **DRUG:** Afatinib
- **DRUG:** Pembrolizumab
- **DRUG:** Panitumumab
- **DRUG:** Carboplatin, pemetrexed, docetaxel, paclitaxel
- **DRUG:** Atezolizumab
- **DRUG:** Palbociclib
- **DRUG:** MVASI® (bevacizumab-awwb)
- **DRUG:** TNO155
- **DRUG:** IV Chemotherapy (Regimen 1)
- **DRUG:** IV Chemotherapy (Regimen 2)
- **DRUG:** BI 1701963
- **DRUG:** AMG 404
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT04185883
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-12-17
- **Primary completion:** 2026-12-17
- **Final completion:** 2027-12-05
- **Target enrollment:** 610 (ACTUAL)
- **Last updated:** 2025-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04185883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04185883, "Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04185883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*